{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:48:02Z","timestamp":1769507282143,"version":"3.49.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004039","name":"Juntendo Institute of Mental Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004039","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.pnpbp.2010.08.027","type":"journal-article","created":{"date-parts":[[2010,9,9]],"date-time":"2010-09-09T08:09:30Z","timestamp":1284019770000},"page":"29-39","source":"Crossref","is-referenced-by-count":27,"title":["Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia"],"prefix":"10.1016","volume":"35","author":[{"given":"Tohru","family":"Ohnuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heii","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2010.08.027_bb0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1523\/JNEUROSCI.16-01-00019.1996","article-title":"Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics","volume":"16","author":"Akbarian","year":"1996","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0010","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s003350010190","article-title":"Identification of two human glutaminase loci and tissue-specific expression of the two related genes","volume":"11","author":"Aledo","year":"2000","journal-title":"Mamm Genome"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0015","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/BF02244049","article-title":"Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients","volume":"101","author":"Alfredsson","year":"1990","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0020","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1176\/ajp.150.11.1731","article-title":"Plasma and platelet excitatory amino acids in psychiatric disorders","volume":"150","author":"Altamura","year":"1993","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0025","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1471-4159.2007.05047.x","article-title":"Differential regulation of the NMDA receptor by acute and sub-chronic phencyclidine administration in the developing rat","volume":"104","author":"Anastasio","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0030","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/sj.npp.1300394","article-title":"Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of d-serine","volume":"29","author":"Andersen","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0035","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0165-1781(91)90062-T","article-title":"Plasma serine in schizophrenics and controls measured by gas chromatography-mass spectrometry","volume":"37","author":"Baruah","year":"1991","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0040","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.nucmedbio.2005.07.004","article-title":"Preferred stereoselective brain uptake of d-serine\u2014a modulator of glutamatergic neurotransmission","volume":"32","author":"Bauer","year":"2005","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2006.10.010","article-title":"A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia","volume":"90","author":"Bendikov","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0050","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0169-328X(97)00326-4","volume":"54","author":"Chen","year":"1998","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0055","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/PL00000638","article-title":"Redox modulation of the NMDA receptor","volume":"57","author":"Choi","year":"2000","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0060","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1111\/j.1471-4159.1989.tb07257.x","article-title":"Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia","volume":"52","author":"Deakin","year":"1989","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000202822","article-title":"Oxidative\/nitrative modifications of plasma proteins and thiols from patients with schizophrenia","volume":"59","author":"Dietrich-Muszalska","year":"2009","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0070","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1046\/j.1460-9568.2000.00229.x","article-title":"Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo","volume":"12","author":"Do","year":"2000","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0075","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1176\/appi.ajp.158.9.1400","article-title":"N-methyl-d-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia","volume":"158","author":"Dracheva","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0080","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0006-3223(99)00133-X","article-title":"IV glycine and oral d-cycloserine effects on plasma and CSF amino acids in healthy humans","volume":"47","author":"D'Souza","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0085","doi-asserted-by":"crossref","first-page":"10404","DOI":"10.1523\/JNEUROSCI.1618-08.2008","article-title":"d-aspartate prevents corticostriatal long-term depression and attenuates schizophrenia-like symptoms induced by amphetamine and MK-801","volume":"28","author":"Errico","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0090","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1515\/REVNEURO.2009.20.5-6.429","article-title":"d-aspartate: an atypical amino acid with neuromodulatory activity in mammals","volume":"20","author":"Errico","year":"2009","journal-title":"Rev Neurosci"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0920-9964(01)00220-1","article-title":"d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia","volume":"56","author":"Evins","year":"2002","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0100","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.euroneuro.2007.12.002","article-title":"Cerebrospinal fluid d-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients","volume":"18","author":"Fuchs","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0105","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1176\/ajp.153.12.1628","article-title":"d-cycloserine added to clozapine for patients with schizophrenia","volume":"153","author":"Goff","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archpsyc.56.1.21","article-title":"A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia","volume":"56","author":"Goff","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0115","first-page":"31","article-title":"Neuromediators in the cerebellar blood\u2013brain barrier and its microenvironment. Immunocytochemical demonstration of taurine, glycine, serotonin, thiamin and AATase","volume":"35","author":"Gragera","year":"1994","journal-title":"J Hirnforsch"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0120","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00002826-199506000-00004","article-title":"The phencyclidine-glutamate model of schizophrenia","volume":"18","author":"Halberstadt","year":"1995","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0125","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.pnpbp.2008.06.012","article-title":"Microglial activation in schizophrenia and minocycline treatment","volume":"32","author":"Hashimoto","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0014-2999(91)90261-N","article-title":"d-alanine inhibits methamphetamine-induced hyperactivity in rats","volume":"202","author":"Hashimoto","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0014-5793(92)80397-Y","article-title":"The presence of free d-serine in rat brain","volume":"296","author":"Hashimoto","year":"1992","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0304-3940(93)90476-2","article-title":"Free d-serine, d-aspartate and d-alanine in central nervous system and serum in mutant mice lacking d-amino acid oxidase","volume":"152","author":"Hashimoto","year":"1993","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0145","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archpsyc.60.6.572","article-title":"Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia","volume":"60","author":"Hashimoto","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0150","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.pnpbp.2005.04.023","article-title":"Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients","volume":"29","author":"Hashimoto","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/1573400054065569","article-title":"Dysfunction of glia-neuron communication in pathophysiology of schizophrenia","volume":"1","author":"Hashimoto","year":"2005","journal-title":"Curr Psychiatry Rev"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0160","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.euroneuro.2007.07.009","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and d-serine","volume":"18","author":"Hashimoto","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.psychres.2010.02.014","article-title":"Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve\u2014results from the Juntendo University Schizophrenia Projects (JUSP)","volume":"177","author":"Hatano","year":"2010","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0170","doi-asserted-by":"crossref","first-page":"867S","DOI":"10.3945\/ajcn.2009.27462BB","article-title":"The blood\u2013brain barrier and glutamate","volume":"90","author":"Hawkins","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0175","doi-asserted-by":"crossref","first-page":"218S","DOI":"10.1093\/jn\/136.1.218S","article-title":"Structure of the blood\u2013brain barrier and its role in the transport of amino acids","volume":"136","author":"Hawkins","year":"2006","journal-title":"J Nutr"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0180","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ebmh.9.2.48","article-title":"Adding sarcosine, but not d-serine, to risperidone improves symptoms in people with acute phase schizophrenia","volume":"9","author":"Heresco-Levy","year":"2006","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0185","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0920-9964(03)00129-4","article-title":"Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis","volume":"66","author":"Heresco-Levy","year":"2004","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archpsyc.56.1.29","article-title":"Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia","volume":"56","author":"Heresco-Levy","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0195","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1176\/appi.ajp.159.3.480","article-title":"Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia","volume":"159","author":"Heresco-Levy","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0200","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0006-3223(03)00707-8","article-title":"High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia","volume":"55","author":"Heresco-Levy","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0205","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.biopsych.2004.12.037","article-title":"d-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia","volume":"57","author":"Heresco-Levy","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0210","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.schres.2006.12.003","article-title":"High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients","volume":"91","author":"Heresco-Levy","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0215","first-page":"485","article-title":"d-serine serum levels in patients with schizophrenia: relation to psychopathology and comparison to healthy subjects","volume":"29","author":"Hons","year":"2008","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0220","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0924-9338(02)00696-X","article-title":"Antiepileptic drugs in schizophrenia: a review","volume":"17","author":"Hosak","year":"2002","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0225","first-page":"12","article-title":"Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia","volume":"9","author":"Javitt","year":"1987","journal-title":"Hillside J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0230","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0235","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1017\/S1461145701002590","article-title":"Adjunctive high-dose glycine in the treatment of schizophrenia","volume":"4","author":"Javitt","year":"2001","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0240","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0269881105051542","article-title":"Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect?","volume":"19","author":"Kalyoncu","year":"2005","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF00365738","article-title":"Reduction of cerebrospinal fluid glutamic acid in Huntington's chorea and in schizophrenic patients","volume":"228","author":"Kim","year":"1980","journal-title":"Arch Psychiatr Nervenkr"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0250","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF00345492","article-title":"Increased serum glutamate in depressed patients","volume":"232","author":"Kim","year":"1982","journal-title":"Arch Psychiatr Nervenkr"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0255","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0896-6273(94)90311-5","article-title":"NMDA receptor channels: subunit-specific potentiation by reducing agents","volume":"12","author":"Kohr","year":"1994","journal-title":"Neuron"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0260","first-page":"581","article-title":"Glutamatergic hypothesis of schizophrenia: psychoses induced by phencyclidine and cortical\u2013subcortical imbalance","volume":"21","author":"Krebs","year":"1995","journal-title":"Encephale"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0265","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.euroneuro.2007.11.001","article-title":"The possible involvement of metabotropic glutamate receptors in schizophrenia","volume":"18","author":"Krivoy","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0270","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/archpsyc.62.11.1196","article-title":"Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"62","author":"Lane","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0275","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.biopsych.2006.04.005","article-title":"Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia","volume":"60","author":"Lane","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0280","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biopsych.2007.04.038","article-title":"Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study","volume":"63","author":"Lane","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0285","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1017\/S1461145709990939","article-title":"A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia","volume":"13","author":"Lane","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0290","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/00000542-198305000-00028","article-title":"Glycine and the blood\u2013brain barrier","volume":"58","author":"Larson","year":"1983","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0295","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.pnpbp.2005.01.012","article-title":"Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-d-aspartate (NMDA) glutamatergic receptor blockade","volume":"29","author":"Levin","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0300","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/01.gim.0000250507.96760.4b","article-title":"Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: a HuGE review and meta-analysis","volume":"9","author":"Li","year":"2007","journal-title":"Genet Med"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0305","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/archneurpsyc.1959.02340150095011","article-title":"Study of a new schizophrenomimetric drug-sernyl","volume":"81","author":"Luby","year":"1959","journal-title":"Arch Neurol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0310","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.pnpbp.2007.06.009","article-title":"Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia - Juntendo University Schizophrenia Projects (JUSP)","volume":"31","author":"Maeshima","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0315","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.pnpbp.2008.11.004","article-title":"Minocycline, schizophrenia and GluR1 glutamate receptors","volume":"33","author":"Manev","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0320","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0920-9964(03)00011-2","article-title":"A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress","volume":"65","author":"Marchbanks","year":"2003","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0325","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/0024-3205(93)90188-9","article-title":"Altered cerebrospinal fluid amino acid pattern in the anorexia of aging: relationship with biogenic amine metabolism","volume":"53","author":"Martinez","year":"1993","journal-title":"Life Sci"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0330","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1046\/j.1471-4159.1995.65010454.x","article-title":"Functional comparison of d-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration","volume":"65","author":"Matsui","year":"1995","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0335","doi-asserted-by":"crossref","first-page":"e1944","DOI":"10.1371\/journal.pone.0001944","article-title":"Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study","volume":"3","author":"Matsuzawa","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0340","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0026-895X(25)09633-6","article-title":"Structural requirements for activation of the glycine coagonist site of N-methyl-d-aspartate receptors expressed in Xenopus oocytes","volume":"36","author":"McBain","year":"1989","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0345","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1523\/JNEUROSCI.22-07-02718.2002","article-title":"Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia","volume":"22","author":"Middleton","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0350","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/WNF.0b013e3181593d45","article-title":"Minocycline as adjunctive therapy for schizophrenia: an open-label study","volume":"31","author":"Miyaoka","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0355","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J Neurosci"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0360","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1176\/appi.ajp.162.9.1738","article-title":"Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type","volume":"162","author":"Neeman","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0365","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1248\/bpb.28.1561","article-title":"Metabolism and functional roles of endogenous d-serine in mammalian brains","volume":"28","author":"Nishikawa","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0370","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0304-3940(83)90046-0","article-title":"Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia","volume":"40","author":"Nishikawa","year":"1983","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0375","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0169-328X(98)00063-1","article-title":"Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia [In Process Citation]","volume":"56","author":"Ohnuma","year":"1998","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0380","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1097\/00001756-200009280-00019","article-title":"Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia","volume":"11","author":"Ohnuma","year":"2000","journal-title":"NeuroReport"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0385","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0169-328X(00)00222-9","article-title":"Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus","volume":"85","author":"Ohnuma","year":"2000","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0390","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0169-328X(03)00051-2","article-title":"Expression of Fyn, a non-receptor tyrosine kinase in prefrontal cortex from patients with schizophrenia and its correlation with clinical onset","volume":"112","author":"Ohnuma","year":"2003","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0395","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.pnpbp.2005.04.038","article-title":"Hypothesis: minimal changes in neural transmission in schizophrenia: decreased glutamatergic and GABAergic functions in the prefrontal cortex","volume":"29","author":"Ohnuma","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0400","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.pnpbp.2008.07.022","article-title":"Changes in plasma glycine, l-serine, and d-serine levels in patients with schizophrenia as their clinical symptoms improve: Results from the Juntendo University Schizophrenia Projects (JUSP)","volume":"32","author":"Ohnuma","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0405","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1152\/ajpendo.00007.2006","article-title":"Cationic amino acid transport across the blood\u2013brain barrier is mediated exclusively by system y+","volume":"291","author":"O'Kane","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0410","doi-asserted-by":"crossref","first-page":"38939","DOI":"10.1074\/jbc.C200373200","article-title":"Nuclear localization of L-type glutaminase in mammalian brain","volume":"277","author":"Olalla","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0415","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archpsyc.1995.03950240016004","article-title":"Glutamate receptor dysfunction and schizophrenia","volume":"52","author":"Olney","year":"1995","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0420","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0165-1781(85)90046-0","article-title":"Interconversion of serine and glycine is normal in psychotic patients","volume":"15","author":"Perry","year":"1985","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0425","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/neu.480070205","article-title":"Movement of glycine across the blood\u2013brain barrier of the rabbit","volume":"7","author":"Pollay","year":"1976","journal-title":"J Neurobiol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0430","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/sj.mp.4001532","article-title":"Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress","volume":"9","author":"Prabakaran","year":"2004","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0435","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1046\/j.1471-4159.1998.71052071.x","article-title":"Role of endogenous glutathione in the oxidation of dopamine","volume":"71","author":"Rabinovic","year":"1998","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0440","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.pnpbp.2009.06.018","article-title":"Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients","volume":"33","author":"Raffa","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0445","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0169-328X(97)00175-7","article-title":"Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs","volume":"50","author":"Riva","year":"1997","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0450","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/j.1471-4159.2004.02592.x","article-title":"Effects of psychotomimetic and antipsychotic agents on neocortical and striatal concentrations of various amino acids in the rat","volume":"90","author":"Sakurai","year":"2004","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0455","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF01244937","article-title":"Phencyclidine treatment in mice: effects on phencyclidine binding sites and glutamate uptake in cerebral cortex preparations","volume":"93","author":"Saransaari","year":"1993","journal-title":"J Neural Transm Gen Sect"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0460","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejphar.2009.09.006","article-title":"Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2\/3) receptor agonist LY354740 in tests for antipsychotic-like activity","volume":"623","author":"Schlumberger","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0465","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/FBP.0b013e3283242f57","article-title":"Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition","volume":"20","author":"Schlumberger","year":"2009","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0470","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pbb.2009.12.002","article-title":"Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia","volume":"95","author":"Schlumberger","year":"2010","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0475","doi-asserted-by":"crossref","first-page":"1016S","DOI":"10.1093\/jn\/130.4.1016S","article-title":"Transport of glutamate and other amino acids at the blood\u2013brain barrier","volume":"130","author":"Smith","year":"2000","journal-title":"J Nutr"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1461145703003900","article-title":"Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms","volume":"7","author":"Sumiyoshi","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0485","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1017\/S1461145705005237","article-title":"Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia","volume":"8","author":"Sumiyoshi","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0490","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1046\/j.1471-4159.1997.69031286.x","article-title":"In vivo evidence for the link between l- and d-serine metabolism in rat cerebral cortex","volume":"69","author":"Takahashi","year":"1997","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0495","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0006-8993(91)91546-D","article-title":"Stereoselective inhibition by d- and l-alanine of phencyclidine-induced locomotor stimulation in the rat","volume":"563","author":"Tanii","year":"1991","journal-title":"Brain Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0500","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0022-3565(25)38840-3","article-title":"Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat","volume":"269","author":"Tanii","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0505","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2009.01.002","article-title":"The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis","volume":"109","author":"Tiihonen","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0510","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000054937","article-title":"Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine","volume":"44","author":"Tortorella","year":"2001","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0515","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0006-3223(98)00279-0","article-title":"d-serine added to antipsychotics for the treatment of schizophrenia","volume":"44","author":"Tsai","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0520","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1176\/ajp.156.11.1822","article-title":"d-serine added to clozapine for the treatment of schizophrenia","volume":"156","author":"Tsai","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0525","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2003.09.012","article-title":"Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia","volume":"55","author":"Tsai","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0530","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.biopsych.2005.06.032","article-title":"d-alanine added to antipsychotics for the treatment of schizophrenia","volume":"59","author":"Tsai","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0535","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/sj.bjp.0701830","article-title":"Characterization of the phencyclidine-induced increase in prefrontal cortical dopamine metabolism in the rat","volume":"124","author":"Umino","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0540","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/glia.20172","article-title":"Clozapine reduces GLT-1 expression and glutamate uptake in astrocyte cultures","volume":"50","author":"Vallejo-Illarramendi","year":"2005","journal-title":"Glia"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0545","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/j.1460-9568.2007.05769.x","article-title":"d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia","volume":"26","author":"Verrall","year":"2007","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0550","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1192\/bjp.143.1.69","article-title":"Plasma serine to cysteine ratio as a biological marker for psychosis","volume":"143","author":"Waziri","year":"1983","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0555","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0165-1781(84)90012-X","article-title":"Serine metabolism and psychosis","volume":"12","author":"Waziri","year":"1984","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0560","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0920-9964(93)90021-A","article-title":"Abnormal serine-glycine metabolism in the brains of schizophrenics","volume":"8","author":"Waziri","year":"1993","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0565","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.nbd.2008.11.018","article-title":"Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation","volume":"33","author":"Wood","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0570","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.biopsych.2005.03.018","article-title":"Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and d-serine levels","volume":"57","author":"Yamada","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0575","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/00023210-200115040-00004","article-title":"Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications","volume":"15","author":"Yao","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2010.08.027_bb0580","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1155\/2006\/248387","article-title":"Altered glutathione redox state in schizophrenia","volume":"22","author":"Yao","year":"2006","journal-title":"Dis Markers"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584610003477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584610003477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T17:23:44Z","timestamp":1740504224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584610003477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0278584610003477"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2010.08.027","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}